<DOC>
	<DOCNO>NCT00317473</DOCNO>
	<brief_summary>To assess safety reactogenicity FMP-1/AS02A malaria vaccine malaria-exposed child live western Kenya age 12-47 month</brief_summary>
	<brief_title>Phase 1 Trial Malaria Vaccine Young Kenyan Children</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A healthy male female child , 12 47 month age time screen . Written inform consent obtain least one parent study start . Available participate duration study ( 12 month ) . Acute disease time entry study Axillary temperature 37.5 degree C Respiratory rate 50 Serum ALT 45 IU/l ( i.e. , &gt; 1.5 X ULN ) Decreased renal function : serum creatinine level &gt; 92.2 mM/l ( &gt; 1.1 mg/dl ) . Significant anemia ( Hgb &lt; 8 gm/dL ) . Thrombocytopenia ( Platelets &lt; 100,000 per mm3 ) Impaired immunity : ( Absolute lymphocyte count [ ALC ] 1 year old &lt; 4.0 x 103/mm3 ; 2 year old &lt; 3.0 x 103/mm3 ; 3 year old &lt; 2.0 103/mm3 . History homozygous sickle cell disease ( SS ) . Malnutrition ( Z score ; Malnutrition = Weight height &lt; 3 z score ) Blood transfusion use bloodbased product previous 6 month . Prior receipt rabies vaccine investigational malaria vaccine . Use investigational drug vaccine study vaccine within 30 day precede first dose study vaccine , plan use 30 day third dose . Administration chronic ( defined 14 day ) immunosuppressant immunemodifying drug within six month vaccination . ( For corticosteroid , mean prednisone , equivalent , great equal 0.5 mg/kg/day . Inhaled topical steroid allow ) . Administration anticipate administration vaccine foreseen study protocol within 30 day first dose vaccine ( ) exception tetanus toxoid . Previous vaccination vaccine contain MPL QS21 ( e.g. , RTS , S ) . Any confirm suspect immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . ( No HIV test undertaken part study . ) History allergic reaction anaphylaxis immunization vaccine component . History surgical splenectomy . Administration immunoglobulins blood product within 3 month precede first dose study vaccine plan administration study period . Simultaneous participation clinical trial . Acute chronic cardiovascular , pulmonary , hepatic renal condition , opinion PI may increase risk subject participate study . Any condition circumstance opinion investigator may pose threat subject .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>47 Months</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Vaccine</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>Malaria</keyword>
	<keyword>Merozoite surface protein-1</keyword>
	<keyword>MSP-1</keyword>
	<keyword>Falciparum malaria protein 1</keyword>
	<keyword>FMP-1</keyword>
	<keyword>AS02A</keyword>
</DOC>